NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
The medication will initially be offered only to those people with the highest clinical needs.
Working alongside people and communities is an essential tool in helping to improve the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
Page 5 of 36
News article listing page, 5 of 36